Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.71M | 6.23M | 5.80M | 5.68M | 5.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.62M | 16.27M | 20.09M | 29.15M | 34.02M |
| Operating Income | -15.62M | -16.27M | -20.09M | -29.15M | -34.02M |
| Income Before Tax | -27.84M | -26.25M | -30.84M | -37.30M | -40.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.84 | -26.25 | -30.84 | -37.30 | -40.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.84M | -26.25M | -30.84M | -37.30M | -40.34M |
| EBIT | -15.62M | -16.27M | -20.09M | -29.15M | -34.02M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.43 | -0.41 | -0.49 | -0.59 | -0.64 |
| Normalized Basic EPS | -0.27 | -0.25 | -0.30 | -0.37 | -0.40 |
| EPS Diluted | -0.43 | -0.41 | -0.49 | -0.59 | -0.64 |
| Normalized Diluted EPS | -0.27 | -0.25 | -0.30 | -0.37 | -0.40 |
| Average Basic Shares Outstanding | 260.61M | 258.18M | 255.60M | 253.60M | 251.68M |
| Average Diluted Shares Outstanding | 260.61M | 258.18M | 255.60M | 253.60M | 251.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |